Akamis Bio, a clinical-stage oncology company using a proprietary Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to ...

INT2104 is a novel in vivo chimeric antigen receptor (CAR) gene therapy designed to generate CAR-T and CAR-NK cells in the patient's body to target CD20-expressing malignant B cells PHILADELPHIA, Oct.

The posters are available on the Posters and Publications page of the Company’s website.

The global Oncolytic Virus Cancer Therapy (OVT) market is expected to be valued at USD 22.86 million in 2023, with ...

Data further validates the AnelloVector™ platform as the first gene delivery vector system based on the human commensal anellovirus CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Ring ...

states a FMI analyst Key players in the oncolytic adenovirus market are Amgen, Sorrento Therapeutics, Transgene SA, Oncolys BioPharma, Targovax, Lokon Pharma, Vyriad, TILT Biotherapeutics, CG Oncology ...